타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr) BeOne Medicines·PD-1 213 trials·t½ ~20 days class range | atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody) Roche / Genentech·Colorectal Cancer 143 trials |
|---|---|---|
Overview Program | Tevimbra (tislelizumab) | Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody |
Overview Company | BeOne Medicines | Roche / Genentech |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | Colorectal Cancer |
Overview Indication | Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and chemotherapy | Triple-Negative Breast Cancer |
Overview Phase | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE |
Overview Content status | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row. | — |
Positioning Known limitation | Antigen-presentation loss, alternate checkpoints, immunosuppressive TME. | — |
Positioning Development positioning | 1L–2L gastroesophageal, regimen-dependent | — |
MoA Mechanism | Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance. | targets in breast cancer and the most important molecular pathway |
MoA Biomarker | PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera. | PD-1 + ) CD8 + T cells follow |
PK/PD Half-life | ~20 days class range | — |
PK/PD Species | OS/PFS, radiographic response | — |
PK/PD Animal (cat.) | Human | — |
Toxicology Major finding | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. | — |
Toxicology CRS | N/A | — |
Clinical Safety signal | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. | — |
Clinical Program phase | APPROVED | PHASE_3 |
Clinical Trial activity | — | No active/completed counts |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 자동 수집 갱신 권장 · 9월 2일
현재 선택: 2개 · 임상 갱신 필요 2개 · Data Tier에서 열림
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tislelizumab (Tevimbra, BGB-A317, tislelizumab-jsgr) BeOne Medicines·PD-1 213 trials·t½ ~20 days class range | atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody) Roche / Genentech·Colorectal Cancer 143 trials |
|---|---|---|
Overview Program | Tevimbra (tislelizumab) | Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody |
Overview Company | BeOne Medicines | Roche / Genentech |
Overview Modality | ANTIBODY | ANTIBODY |
Overview Target | PD-1 | Colorectal Cancer |
Overview Indication | Esophageal squamous cell carcinoma, gastric/GEJ adenocarcinoma, and first-line HER2-positive GEA with zanidatamab and chemotherapy | Triple-Negative Breast Cancer |
Overview Phase | APPROVED | PHASE_3 |
Overview Status | APPROVED | ACTIVE |
Overview Content status | Curated Core | Limited Data |
Overview Data Confidence | Editorial scope · Curated Core | Editorial scope · limited data |
Overview Development Signal | Development Signal · Established | Development Signal · Emerging |
Overview Approval status | FDA approved | Investigational |
Positioning Key differentiator | Not a Keytruda substitute. The 2026 GEA label is a HER2-selected triplet with zanidatamab, not a PD-L1-unselected 1L PD-1 row. | — |
Positioning Known limitation | Antigen-presentation loss, alternate checkpoints, immunosuppressive TME. | — |
Positioning Development positioning | 1L–2L gastroesophageal, regimen-dependent | — |
MoA Mechanism | Binds PD-1 on T cells, blocking PD-L1/PD-L2 engagement and restoring antitumor T-cell activity. Fc silencing is intended to avoid macrophage-mediated T-cell clearance. | targets in breast cancer and the most important molecular pathway |
MoA Biomarker | PD-L1 and tumor type on older labels; HER2 IHC/ISH when given with Ziihera. | PD-1 + ) CD8 + T cells follow |
PK/PD Half-life | ~20 days class range | — |
PK/PD Species | OS/PFS, radiographic response | — |
PK/PD Animal (cat.) | Human | — |
Toxicology Major finding | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. | — |
Toxicology CRS | N/A | — |
Clinical Safety signal | Immune-mediated pneumonitis, colitis, hepatitis, endocrinopathies, and infusion-related reactions. Allogeneic transplant complications are labeled. | — |
Clinical Program phase | APPROVED | PHASE_3 |
Clinical Trial activity | — | No active/completed counts |
추천 비교
추천 비교